Revlimid (lenalidomide) - risk of liver problems

Celgene Inc., in collaboration with Health Canada, would like to inform you of important new safety information which has been added to the Product Monograph for REVLIMID® (lenalidomide) capsules. REVLIMID® is indicated in combination with dexamethasone for the treatment of multiple myeloma (MM) in patients who have received at least one prior therapy. Read more here.